SLG
LKFT

Stanley-Laman Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Stanley-Laman Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,810
Closed -$720K – 230
2018
Q2 		$720K Buy
+7,810
New +$758K 0.16% 182

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Stanley-Laman Group's LKFT Position: Q3 2018 in Review

Stanley-Laman Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2018, closing a stake of 7,810 shares — an estimated $720K sold.

Stanley-Laman Group first reported a position in LKFT in Q2 2018 and held it in 1 quarter. The position peaked at $720K in Q2 2018. 92 funds tracked by Wall St. Rank hold LKFT as of Q3 2018.

  • Stanley-Laman Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 7,810 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2018, an estimated $720K.
  • Stanley-Laman Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $720K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.